Filing Details

Accession Number:
0001447028-24-000028
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-05 19:55:02
Reporting Period:
2024-02-01
Accepted Time:
2024-02-05 19:55:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1447028 Arbutus Biopharma Corp ABUS Pharmaceutical Preparations (2834) 980597776
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1984652 Karen Sims C/O Arbutus Biopharma Corporation
701 Veterans Circle
Warminster PA 18974
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2024-02-01 101,000 $0.00 129,900 No 4 A Direct
Common Shares Disposition 2024-02-02 4,358 $2.31 125,542 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Stock Option (Right to Buy) Acquisiton 2024-02-01 403,900 $0.00 403,900 $2.40
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
403,900 2034-02-01 No 4 A Direct
Footnotes
  1. Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
  2. Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 9, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of a previous grant of restricted stock units.
  3. Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
  4. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.